DGAP-News: Dermapharm continues to drive development of new products

Dermapharm continues to drive development of new products

• New products for the treatment of acute hay fever symptoms open up significant market potential
• bite away^(R) successful in all distribution channels and receives award as one of the OTC growth champions

Grünwald, February 21, 2019 - Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil^(R) and Momekort^(R) in Germany just in time for the hay fever season. In addition, the patented medical product bite away^(R) from the 2018 Hyperthermia range has performed well in all sales channels.

Since January 2019, Dermapharm has been offering the self-developed product Azedil^(R) in Germany for treatment of acute hay fever problems in the eyes and nose. Azedil^(R) is an antihistamine that is available individually as both a nasal spray and eye drops or in a combination pack. Dermapharm has also been offering Momekort^(R), a prescription-free nasal spray for adults that contains cortisone, for more severe symptoms caused by allergic symptoms of the nose since February 2019. The nasal spray has a local anti-allergic, anti-inflammatory and decongestant effect against hay fever symptoms. Momekort^(R) has no sedative or habituation effect and can therefore be used throughout the entire hay fever season.

Due to the strong increase in allergies in the population, the demand for anti-allergic preparations is constantly growing⁽¹⁾. Just in time for the start of the main season for hay fever, which is usually from February to the end of July, Dermapharm has already stocked many pharmacies in Germany with the products Azedil^(R) and Momekort^(R).

Dermapharm had already strengthened its OTC portfolio with the hyperthermal medical product bite away^(R) at the end of 2017. The patented product is used for the symptomatic treatment of itching, pain and swelling caused by insect bites and stings. Since the acquisition of the technology, Dermapharm has been able to market bite away^(R) very successfully in Germany and many other countries.

In 2018, the specialist magazine "HEALTHCARE MARKETING," in cooperation with the market research institute "Insight Health," has identified bite away^(R) to be one of the fastest growing OTC products in pharmacies - offline and online. bite away has also developed very positively in other channels such as drugstores and e-commerce, occupying the top positions in the respective segments.

(1) European Centre for Allergy Research Foundation, Allergies - Facts and Figures, 2018.

Company profile:

Dermapharm - Pharmaceutical Excellence "Made in Germany"

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company's integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 950 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, food supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company's core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm's business model also includes a parallel import business, which operates under the "axicorp" brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in the first half-year 2018.

With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican^(R) forte and Tromcardin^(R) complex.

Contacts